| 43.27 Delayed Data As of Oct 23 |  +0.75 / +1.76%Today’s Change | 36.41 Today|||52-Week Range 43.31 | +13.24% Year-to-Date |
| Is AnaptysBio a Buy? Oct 23 / MotleyFool.com - Paid Partner Content | Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding? Oct 11 / MotleyFool.com - Paid Partner Content |
| Better Buy: GlaxoSmithKline vs. Merck Oct 15 / MotleyFool.com - Paid Partner Content |
| Previous close | 42.52 |
| Today’s open | 43.10 |
| Day’s range | 42.96 - 43.31 |
| Volume | 3,335,414 |
| Average volume (3 months) | 2,301,449 |
| Market cap | $106.1B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -6.95% |
| Earnings growth (next 5 years) | +3.50% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 18.9 |
| Price/Sales | 2.31 |
| Price/Book | 18.85 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | -2.44 | -2.22% |
| SNYSanofi | +0.45 | +0.99% |
| ABBVAbbVie | -0.12 | -0.15% |
| AZNAstraZeneca | +0.77 | +1.75% |
| Last reporting date | -- |
| EPS forecast (this quarter) | $0.81 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Brentford, Greater London |
